PF-114|CAS 1416241-23-0|DC Chemicals

Cas No.:	1416241-23-0
Chemical Name:	Vamotinib
Synonyms:	PF-114 1416241-23-0;Vamotinib (Synonyms: PF-114);Vamotinib;PF-114;GTPL9792;Bcr-Abl Kinase Inhibitor PF-114;US9522910, Table 1 Compound 1: 4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{[1,2,4]triazolo[4,3-a]pyridin-3-yl}ethynyl)benzamide;Bcr-Abl Inhibitor PF-114;MS-29841;1416241-23-0;PF114;4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-([1,2,4]triazolo[4,3-a]pyridin-3-yl)ethynyl]benzamide;4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-[([1,2,4]triazolo[4,3-a]pyridin-3-yl)ethynyl]benzamide;SCHEMBL15789568;DB15396;DA-78825;CS-0564153;UNII-I8C3R768IZ;3-([1,2,4]Triazolo[4,3-a]pyridin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;CHEMBL4297478;HY-147414;vamotinib [INN];4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{[1,2,4]triazolo[4,3-a]pyridin-3-yl}ethynyl)benzamide;I8C3R768IZ;SLIVDYMORZGPLW-UHFFFAOYSA-N;compound 1 (Table 1) [WO2012173521];Benzamide, 4-methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1,2,4-triazolo(4,3-a)pyridin-3-yl)ethynyl)-
SMILES:	C(NC1=CC=C(CN2CCN(C)CC2)C(C(F)(F)F)=C1)(=O)C1=CC=C(C)C(C#CC2N3C(=NN=2)C=CC=C3)=C1
Formula:	C₂₉H₂₇F₃N₆O
M.Wt:	532.559496164322
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC72877	PF-114	Vamotinib (PF-114) is a potent, selective and orally available inhibitor of native (IC50=0.49 nM) and mutated BCR/ABL (IC50=0.7-4 nM, ABL (T315I) IC50=0.78 nM). PF-114 potently inhibits ABL2, DDR1, DDR2, FMS, FRK, LCK, LYN and PDGFR kinases, but did not inhibit c-SRC, CSK, or c-KIT.
DC44827	Vodobatinib	Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research.
DC41084	GZD824 dimesylate	GZD824 dimesylate (HQP1351 dimesylate) is an orally bioavailable pan-Bcr-Abl inhibitor with potency against a wide range of Bcr-Abl mutants and the native enzyme (IC50=0.34 nM). GZD824 dimesylate has antitumor activity.
DC4181	Imatinib mesylate	Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.
DC9285	GNF-7	GNF-7 is a potent type-II kinase Bcr-Abl inhibitor with IC50 of <5 nM, 61 nM, 122 nM, 136 nM, and 133 nM for M351T, T315I, E255 V, G250E, and c-Abl, respectively.
DC10060	Dianilinopyrimidine_01(CZC8004)	Dianilinopyrimidine_01 is a Pan Tyrosine kinase inhibitor.
DC5041	DCC-2036 (Rebastinib)	DCC-2036 is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1/2.
DC1020	Ponatinib (AP24534)	AP24534 is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.